Depixus

Depixus, a Paris-based life science technology company, is redefining the biotechnology landscape with its pioneering technology in magnetic force spectroscopy. This cutting-edge solution enables real-time analysis of individual biomolecular interactions on a vast scale, offering new avenues for researchers to decode disease mechanisms and accelerate the development of effective therapies. Founded in 2012, Depixus aims to revolutionize how biology is studied by allowing scientists to "See biology as it happens."

As of December 2021, Depixus secured a €30.60M Series A investment, highlighting investor confidence in its innovative approach. The round attracted notable investors including Bpifrance, Casdin Capital, Arix Bioscience, and Lansdowne Partners. With its headquarters in France, Depixus is well-positioned in the thriving European biotechnology industry and poised to capitalize on future growth opportunities.